EDB-102 represents a novel approach in the treatment of advanced non-small cell lung cancer (NSCLC) with liver metastases, specifically targeting patients with the EGFR L858R mutation who have shown resistance to third-generation EGFR-TKIs like osimertinib. The market for NSCLC therapies is substantial, with a growing demand for innovative treatments that address resistance mechanisms. The unique mechanism of action of EDB-102 positions it favorably against existing therapies, potentially offering a competitive edge in a crowded market. The study's focus on a specific mutation and patient population may enhance its attractiveness to investors and partners, particularly as the clinical landscape evolves towards personalized medicine.